Company news from the 03/13/07 news brief

Share this article:
A New Jersey jury on Monday ordered Merck to pay $47.5 million in damages after finding the drugmaker’s Vioxx was responsible for a plaintiff’s heart attack. Merck said it intends to appeal the verdict and the damages. European database and software solutions provider Cegedim has announced plans to acquire sales, marketing solution provider Dendrite in a deal worth approximately $751 million. Dorland Global Corporation launched a new Web site at dorland.com, featuring a blog by Dorland Global co-founder, Harry Sweeney, a longtime advertising agency veteran who also serves as chair of the Coalition for Healthcare Communications. The blog will feature guest diarists, including agency executives, clients and colleagues in the healthcare communications industry, according to a news release. Publicis Groupe has acquired sales, marketing and Prescription Drug Marketing Act (PDMA) compliance firm Pharmagistics. Financial terms of the deal were not disclosed. Pharmagistics, based in Somerset, NJ, offers four key services including distribution of samples and literature to pharmaceutical sales forces, direct marketing solutions (direct-to-practitioner), PDMA compliant sample accountability services and specialty logistical services. Pharmagistics will remain a separate unit with its own identity operating within Publicis Groupe's Publicis Healthcare Communications Group, a Publicis Groupe news release said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...